Bicara Therapeutics (NASDAQ:BCAX) Issues Quarterly Earnings Results

Bicara Therapeutics (NASDAQ:BCAX) issued its quarterly earnings results on Tuesday. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($1.14), Zacks reports.

Bicara Therapeutics Trading Up 0.7 %

Shares of NASDAQ:BCAX traded up $0.15 on Wednesday, reaching $22.50. 152,879 shares of the company traded hands, compared to its average volume of 356,837. The business has a 50-day simple moving average of $23.46. Bicara Therapeutics has a 52 week low of $18.33 and a 52 week high of $28.09.

Insider Activity

In other news, Director Ra Capital Management, L.P. acquired 1,833,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the acquisition, the director now directly owns 4,303,418 shares in the company, valued at approximately $77,461,524. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. In other news, major shareholder James E. Flynn acquired 70,000 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were purchased at an average price of $18.00 per share, with a total value of $1,260,000.00. Following the transaction, the insider now directly owns 897,587 shares in the company, valued at approximately $16,156,566. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ra Capital Management, L.P. acquired 1,833,000 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the transaction, the director now owns 4,303,418 shares in the company, valued at approximately $77,461,524. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on BCAX shares. TD Cowen started coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating for the company. Cantor Fitzgerald began coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set an “overweight” rating for the company. Morgan Stanley began coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set an “overweight” rating and a $35.00 price objective for the company. Rodman & Renshaw started coverage on Bicara Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating and a $48.00 price objective for the company. Finally, RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Bicara Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $43.33.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.